Login
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

cardiffoncology.com

What Do They Do?

Develops onvansertib, an oral cancer drug candidate used with standard cancer treatments for colorectal, pancreatic, lung and breast cancers, and blood cancers.

How Do They Make Money?

Receives royalties tied to sales or use of intellectual property licenses unrelated to onvansertib; payment timing depends on licensees’ sales activity. It also licenses patent rights to healthcare companies, medical laboratories and biotechnology partners.

FY2025 revenue

Who Are Their Customers?

Healthcare companies, medical laboratories and biotechnology partners license patent rights from the company.

Do Revenues Turn Into Profits?

No. It lost $45.9M in FY2025.

Operating income, FY2025
−8256% of revenue
▼ −1% (Loss) vs FY2024 (−$48.7M, −7123%)
Net income, FY2025
−7732% of revenue
▼ −1% (Loss) vs FY2024 (−$45.4M, −6652%)
Free cash flow, FY2025
−6403% of revenue
▼ −1% (Loss) vs FY2024 (−$37.8M, −5530%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +43%
vs $120K in Q3 FY2025
Net income
▲ +21% (Loss)
vs −$11.3M in Q3 FY2025
  • Sep 14, 2026 Settled dispute and amended the onvansertib license agreement The agreement resolves the dispute and changes the terms governing the company’s rights to develop and commercialize onvansertib.

Growing. Revenue grew 65% in 4 years, from $359K in FY2021 to $593K in FY2025, about 13% a year.

Clinical focus The latest report adds trials in chronic myelomonocytic leukemia and focuses the colorectal cancer program on first-line RAS-mutated disease; the older report described a second-line colorectal cancer program.

Who Do They Compete With?

Competes with Boehringer Ingelheim, Cyclacel, BMS, Amgen, Pfizer, and Summit Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support